Oxaliplatina Kabi

Oxaliplatin, the active ingredient in Oxaliplatina Kabi, is a platinum‑based chemotherapy presented as a strength/form for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatina Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatina Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is used in the treatment of cancers that involve the colorectal pathway:

- Colorectal cancer: Improves the overall response to standard chemotherapy regimens. - Gastric cancer: Used in combination with other agents to enhance tumor reduction. - Pancreatic cancer: Contributes to disease control when part of multi‑drug protocols. - Ovarian cancer: Provides additional cytotoxic effect in platinum‑sensitive cases. - Esophageal cancer: Used alongside other chemotherapeutics to improve response rates. - Peritoneal carcinomatosis: Applied as part of hyper‑hyper‑HIHI treatment protocols.

Oxaliplatin may cause a range of adverse reactions during and after treatment.

Common Side Effects: - Nausea - Fatigue - Peripheral neuropathy - Diarrhea - Thrombocytopenia - Anemia

Serious or Rare Side Effects: - Severe allergic reactions - Acute lung injury - Cardiac arrhythmias - Severe neutropenia - Hepatotoxic .

Oxaliplatin should be administered as the    ");

"""  """  \n " "" """"""""""""""""""  " """ """"" ".

""  t ",